Blog
RSS FeedPosted by Michael Wonder on 17 Sep 2020
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
16 September 2020 - Next generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly ...
Posted by Michael Wonder on 17 Sep 2020
ChemoCentryx announces FDA acceptance of the avacopan new drug application for the treatment of ANCA associated vasculitis
17 September 2020 - FDA sets PDUFA goal date of 7 July 2021. ...
Posted by Michael Wonder on 17 Sep 2020
Eton Pharmaceuticals provides update on the FDA review of EM-100
16 September 2020 - Eton Pharmaceuticals reported that its partner has not yet received a communication from the U.S. FDA regarding ...
Posted by Michael Wonder on 17 Sep 2020
Coronavirus vaccine: Donald Trump contradicts CDC director Robert Redfield
17 September 2020 - Donald Trump has issued an extraordinary public rebuke to his own government’s top health official, labelling him ...
Posted by Michael Wonder on 16 Sep 2020
Up is down — pharmaceutical industry caution versus federal acceleration of COVID-19 vaccine approval
15 September 2020 - Nine pharmaceutical company leaders took the unprecedented step on 8 September 2020, of stating that they would ...
Posted by Michael Wonder on 16 Sep 2020
FDA granted paediatric disease designation for OXi-4503
16 September 2020 - Treatment of acute myeloid leukaemia due to genetic mutations that disproportionately affect paediatric patients. ...
Posted by Michael Wonder on 16 Sep 2020
Orphazyme announces U.S. FDA acceptance and priority review of new drug application for arimoclomol for Niemann-Pick disease Type C
16 September 2020 - If approved, arimoclomol would become the first approved therapy in the U.S. for people with Niemann-Pick disease ...
Posted by Michael Wonder on 16 Sep 2020
MediWound announces FDA acceptance of biologics license application for NexoBrid for the treatment of severe thermal burns
16 September 2020 - MediWound today announced that the U.S. FDA has accepted for review its recently submitted biologics license application ...
Posted by Michael Wonder on 15 Sep 2020
Gilead’s magrolimab, an investigational anti-CD47 monoclonal antibody, receives FDA breakthrough therapy designation for treatment of myelodysplastic syndrome
15 September 2020 - On-going clinical program includes the Phase 3 ENHANCE trial in myelodysplastic syndrome. ...
Posted by Michael Wonder on 15 Sep 2020
FDA publishes comparative performance data for COVID-19 molecular diagnostic tests
15 September 2020 - Today, the U.S. FDA published comparative performance data for some authorised COVID-19 molecular diagnostic tests. ...
Posted by Michael Wonder on 15 Sep 2020
Estimating risk ratios and risk differences: alternatives to odds ratios
15 September 2020 - The goal of many medical research studies is to estimate the direction and magnitude of the effect ...
Posted by Michael Wonder on 15 Sep 2020
Rep Grothman introduces bill for automatic insulin biosimilar interchangeablity
15 September 2020 - Representative Glenn Grothman, (R-Wisconsin), says interchangeability for insulins makes sense based on the savings potential and safety ...
Posted by Michael Wonder on 15 Sep 2020
NIH 'very concerned' about serious side effect in AstraZeneca coronavirus vaccine trial
15 September 2020 - The FDA is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that ...
Posted by Michael Wonder on 15 Sep 2020
Apellis announces submission of pegcetacoplan marketing applications to FDA and EMA for patients with PNH
15 September 2020 - -- Apellis Pharmaceuticals today announced that the company has submitted a new drug application to the ...
Posted by Michael Wonder on 15 Sep 2020
Plus Therapeutics receives fast track designation from FDA for its novel glioblastoma treatment
15 September 2020 - Plus Therapeutics today announced that the U.S. FDA has granted the Company fast track designation for its ...